Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $634.14 in the prior trading day, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed at $640.14, up 0.95%. In other words, the price has increased by $0.95 from its previous closing price. On the day, 1.25 million shares were traded. REGN stock price reached its highest trading level at $644.0 during the session, while it also had its lowest trading level at $629.02.
Ratios:
Our goal is to gain a better understanding of REGN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.10. For the most recent quarter (mrq), Quick Ratio is recorded 3.95 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 05, 2025, Upgraded its rating to Outperform and sets its target price to $834 from $762 previously.
On January 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $1130 to $738.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 69327167488 and an Enterprise Value of 62437081088. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.72, and their Forward P/E ratio for the next fiscal year is 13.84. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.74. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.93 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 4.396 whereas that against EBITDA is 13.491.
Stock Price History:
The Beta on a monthly basis for REGN is 0.43, which has changed by -0.34374416 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $633.10. The 50-Day Moving Average of the stock is -6.78%, while the 200-Day Moving Average is calculated to be -28.83%.
Shares Statistics:
The stock has traded on average 917.71K shares per day over the past 3-months and 955180 shares per day over the last 10 days, according to various share statistics. A total of 107.80M shares are outstanding, with a floating share count of 105.40M. Insiders hold about 3.59% of the company’s shares, while institutions hold 86.36% stake in the company. Shares short for REGN as of 1741910400 were 3249157 with a Short Ratio of 3.54, compared to 1739491200 on 2204900. Therefore, it implies a Short% of Shares Outstanding of 3249157 and a Short% of Float of 3.1400003.
Dividends & Splits
In the trailing 12 months, REGN’s forward annual dividend rate was 0.0, compared to 0.88 this year. Against a Trailing Annual Dividend Yield of 0.0
